Certara (CERT) closed at $9.45 on Oct 19, 2026, up 0.9% on the day. The stock is up 12.2% over the past month, up 38.0% over three months, up 7.3% year to date and down 25.4% over the past year. It trades 27.0% below its 52-week high of $12.94 and 112.4% above its 52-week low of $4.45. The close sits above its 50-day moving average ($8.57) and above its 200-day moving average ($7.21).
NextPick tracks CERT in its AI Drug Discovery basket alongside TEM, ABCL, RXRX, SDGR and ABSI. As of Oct 19, 2026, the basket's money-flow score is -38 (outflow), and the basket is down 6.9% over five sessions. Over the past month CERT ranks 1st of 6 basket members by price change.
Yes — the Oct 19, 2026 close of $9.45 is 31.1% above the 200-day average of $7.21.
CERT closed 27.0% below its 52-week high of $12.94.
NextPick groups CERT with TEM, ABCL, RXRX, SDGR and ABSI in its AI Drug Discovery basket.
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
